Epoch Investment Partners Inc. Sells 63,247 Shares of Halozyme Therapeutics, Inc. $HALO

Epoch Investment Partners Inc. cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 533,359 shares of the biopharmaceutical company’s stock after selling 63,247 shares during the period. Epoch Investment Partners Inc.’s holdings in Halozyme Therapeutics were worth $35,895,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Brown Advisory Inc. increased its holdings in shares of Halozyme Therapeutics by 2.6% in the 4th quarter. Brown Advisory Inc. now owns 35,870 shares of the biopharmaceutical company’s stock worth $2,414,000 after buying an additional 905 shares during the last quarter. Kestra Advisory Services LLC increased its holdings in shares of Halozyme Therapeutics by 71.6% in the 4th quarter. Kestra Advisory Services LLC now owns 11,706 shares of the biopharmaceutical company’s stock worth $788,000 after buying an additional 4,885 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Halozyme Therapeutics by 26.3% in the 4th quarter. Marshall Wace LLP now owns 497,200 shares of the biopharmaceutical company’s stock worth $33,462,000 after buying an additional 103,445 shares during the last quarter. Segall Bryant & Hamill LLC increased its holdings in shares of Halozyme Therapeutics by 41.9% in the 4th quarter. Segall Bryant & Hamill LLC now owns 307,224 shares of the biopharmaceutical company’s stock worth $20,676,000 after buying an additional 90,655 shares during the last quarter. Finally, Bridgewater Associates LP increased its holdings in shares of Halozyme Therapeutics by 15.3% in the 4th quarter. Bridgewater Associates LP now owns 561,577 shares of the biopharmaceutical company’s stock worth $37,794,000 after buying an additional 74,496 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on HALO. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. UBS Group restated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Price Performance

HALO stock opened at $69.50 on Monday. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The company has a 50-day moving average price of $67.51 and a 200 day moving average price of $68.72. The stock has a market cap of $8.24 billion, a PE ratio of 25.00, a P/E/G ratio of 0.29 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the previous year, the company earned $1.11 EPS. The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $66.21, for a total value of $107,591.25. Following the completion of the sale, the director directly owned 43,669 shares of the company’s stock, valued at $2,891,324.49. The trade was a 3.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 93,250 shares of company stock valued at $6,299,746. 2.50% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.